Bristol-Myers Squibb Stock News

Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to 34.78% net gains for top-ten BBB dogs by September 2026, with an average estimated gain of 23.96% and lower-than-market volatility. Five of the lowest-priced, highest-yield BBB stocks - CAG, PFE, ...

Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®.

Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - President of Cell Therapy Organization Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies.

Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in part to recent challenges in the company's drug pipeline, including underwhelming late-stage results for its cardiovascular treatment, Camzyos, as well as its schizophrenia medication, Cobenfy.

Investors looking for dividend stocks that offer high yields and steady payout growth keep noticing Bristol Myers Squibb (BMY -0.08%). The pharmaceutical giant's dividend payout has been moving in the right direction for 25 years.

Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.